Micromet To Participate in the 2010 RBC Capital Markets Healthcare Conference
BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ — Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 – 3, 2010 in New York City. Christian Itin, Ph.D., the Company’s President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET.
The panel discussion will be webcast live and may be accessed at: http://www.wsw.com/webcast/rbc116/panel1/. A replay of the webcast will also be available on the Company’s website at www.micromet-inc.com.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTEÃ‚® technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.